David R Lairson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8275115/publications.pdf

Version: 2024-02-01

81 papers 2,195 citations

304743 22 h-index 243625 44 g-index

81 all docs

81 docs citations

81 times ranked 2901 citing authors

#	Article	IF	CITATIONS
1	The Cost of Epilepsy in the United States: An Estimate from Population-Based Clinical and Survey Data. Epilepsia, 2000, 41, 342-351.	5.1	504
2	AMIGAS: A multicity, multicomponent cervical cancer prevention trial among Mexican American women. Cancer, 2013, 119, 1365-1372.	4.1	92
3	The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. Oral Oncology, 2018, 82, 91-99.	1.5	77
4	Prevention of Herpes Simplex Virus Eye Disease. JAMA Ophthalmology, 2003, 121, 108.	2.4	76
5	Sociodemographic disparities in epilepsy care: Results from the Houston/New York City health care use and outcomes study. Epilepsia, 2009, 50, 1040-1050.	5.1	73
6	Cost-Effectiveness of Alternative Methods for Diabetic Retinopathy Screening. Diabetes Care, 1992, 15, 1369-1377.	8.6	72
7	A Randomized Controlled Trial of a Tailored Interactive Computer-Delivered Intervention to Promote Colorectal Cancer Screening: Sometimes More is Just the Same. Annals of Behavioral Medicine, 2011, 41, 284-299.	2.9	72
8	Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey. Lancet Public Health, The, 2020, 5, e484-e492.	10.0	72
9	Socioeconomic status, health care use, and outcomes: Persistence of disparities over time. Epilepsia, 2011, 52, 957-964.	5.1	70
10	Estimating the Cost of Epilepsy. Epilepsia, 1999, 40, 8-13.	5.1	63
10	Estimating the Cost of Epilepsy. Epilepsia, 1999, 40, 8-13. Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502.	5.1 5.9	63 58
	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United		
11	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502. Benefits of stroke treatment delivered using a mobile stroke unit trial. International Journal of	5.9	58
11 12	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502. Benefits of stroke treatment delivered using a mobile stroke unit trial. International Journal of Stroke, 2018, 13, 321-327. Risks of Major Longâ€Term Side Effects Associated with Androgenâ€Deprivation Therapy in Men with	5.9 5.9	58
11 12 13	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502. Benefits of stroke treatment delivered using a mobile stroke unit trial. International Journal of Stroke, 2018, 13, 321-327. Risks of Major Longâ€Term Side Effects Associated with Androgenâ€Deprivation Therapy in Men with Prostate Cancer. Pharmacotherapy, 2018, 38, 999-1009. Costâ€effectiveness of targeted and tailored interventions on colorectal cancer screening use. Cancer,	5.9 5.9 2.6	58 50 50
11 12 13	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502. Benefits of stroke treatment delivered using a mobile stroke unit trial. International Journal of Stroke, 2018, 13, 321-327. Risks of Major Longâ€Term Side Effects Associated with Androgenâ€Deprivation Therapy in Men with Prostate Cancer. Pharmacotherapy, 2018, 38, 999-1009. Costâ€effectiveness of targeted and tailored interventions on colorectal cancer screening use. Cancer, 2008, 112, 779-788.	5.9 5.9 2.6 4.1	58 50 50 48
11 12 13 14	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502. Benefits of stroke treatment delivered using a mobile stroke unit trial. International Journal of Stroke, 2018, 13, 321-327. Risks of Major Longâ€Term Side Effects Associated with Androgenâ€Deprivation Therapy in Men with Prostate Cancer. Pharmacotherapy, 2018, 38, 999-1009. Costâ€effectiveness of targeted and tailored interventions on colorectal cancer screening use. Cancer, 2008, 112, 779-788. Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 155. Determinants of the demand for breast cancer screening among women veterans in the United States.	5.9 5.9 2.6 4.1	58 50 50 48 48

#	Article	IF	CITATIONS
19	Projected oropharyngeal carcinoma incidence among middleâ€aged US men. Head and Neck, 2019, 41, 3226-3234.	2.0	33
20	Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget, 2017, 8, 112516-112529.	1.8	32
21	Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecologic Oncology, 2017, 145, 108-113.	1.4	28
22	Medical Care Cost of Oropharyngeal Cancer among Texas Patients. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1443-1449.	2.5	26
23	Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. The Lancet Regional Health Americas, 2022, 8, 100143.	2.6	25
24	Geographic Variation and Sociodemographic Disparity in the Use of Oxaliplatin-Containing Chemotherapy in Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2013, 12, 113-121.	2.3	23
25	Promoting Regular Mammography Screening I. A Systematic Assessment of Validity in a Randomized Trial. Journal of the National Cancer Institute, 2008, 100, 333-346.	6. 3	21
26	The Effect of National Cancer Screening on Disparity Reduction in Cancer Stage at Diagnosis by Income Level. PLoS ONE, 2015, 10, e0136036.	2.5	21
27	A Randomized Trial to Compare a Tailored Web-Based Intervention and Tailored Phone Counseling to Usual Care for Increasing Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1433-1441.	2.5	21
28	Cost Effectiveness of Interventions to Promote Screening for Colorectal Cancer: A Randomized Trial. Journal of Preventive Medicine and Public Health, 2011, 44, 101-110.	1.9	21
29	Against Colorectal Cancer in Our Neighborhoods, a Community-Based Colorectal Cancer Screening Program Targeting Low-Income Hispanics. Health Promotion Practice, 2015, 16, 656-666.	1.6	19
30	Development costs of a computer-generated tailored intervention. Evaluation and Program Planning, 2004, 27, 161-169.	1.6	18
31	Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer. Value in Health, 2015, 18, 387-395.	0.3	18
32	Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients. Drugs - Real World Outcomes, 2016, 3, 69-82.	1.6	17
33	Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. Gynecologic Oncology, 2018, 148, 342-348.	1.4	17
34	Concordance of survey and billing data in a study of outpatient healthcare cost and utilization among epilepsy patients. Epilepsy Research, 2009, 87, 59-69.	1.6	16
35	Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. Pharmacoeconomics, 2015, 33, 1155-1185.	3.3	16
36	Estimating Development Cost for a Tailored Interactive Computer Program to Enhance Colorectal Cancer Screening Compliance. Journal of the American Medical Informatics Association: JAMIA, 2006, 13, 476-484.	4.4	14

#	Article	IF	Citations
37	Cost-effectiveness of targeted versus tailored interventions to promote mammography screening among women military veterans in the United States. Evaluation and Program Planning, 2011, 34, 97-104.	1.6	14
38	Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective. Journal of Managed Care & Decialty Pharmacy, 2017, 23, 831-843.	0.9	14
39	Clinical and Economic Outcomes Associated with Adjuvant Chemotherapy in Elderly Patients with Early Stage Operable Breast Cancer. Value in Health, 2012, 15, 72-80.	0.3	13
40	Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population. Value in Health, 2017, 20, 809-818.	0.3	12
41	Cost-Effectiveness of Community Interventions for Colorectal Cancer Screening: Low-Income Hispanic Population. Health Promotion Practice, 2018, 19, 863-872.	1.6	12
42	The cost of implementing a 2-1-1 call center-based cancer control navigator program. Evaluation and Program Planning, 2013, 39, 51-56.	1.6	11
43	Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with StageÂIII Colon Cancer. Pharmacoeconomics, 2014, 32, 1005-1013.	3.3	11
44	Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Populationâ€Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992–2009. Journal of the American Geriatrics Society, 2015, 63, 1570-1582.	2.6	11
45	Cost-Utility Analysis of Platinum-Based Chemotherapy versus Taxane and Other Regimens for Ovarian Cancer. Value in Health, 2014, 17, 34-42.	0.3	10
46	Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Value in Health, 2015, 18, 1070-1078.	0.3	10
47	Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab. Lung Cancer, 2015, 90, 442-450.	2.0	10
48	An RCT to Increase Breast and Colorectal Cancer Screening. American Journal of Preventive Medicine, 2020, 59, e69-e78.	3.0	10
49	Cervical Cancer Screening with AMIGAS. American Journal of Preventive Medicine, 2014, 46, 617-623.	3.0	9
50	The cost of developing a computerized tailored interactive multimedia intervention vs. a print based Photonovella intervention for HPV vaccine education. Evaluation and Program Planning, 2017, 63, 1-6.	1.6	9
51	Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1156-1164.	0.9	8
52	Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review. Pharmacoeconomics, 2019, 37, 1421-1449.	3.3	8
53	Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Medical Oncology, 2013, 30, 440.	2.5	7
54	The cost of implementing two small media interventions to promote HPV vaccination. Preventive Medicine, 2017, 99, 277-281.	3.4	7

#	Article	IF	CITATIONS
55	Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. Medical Oncology, 2017, 34, 153.	2.5	7
56	Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US. Scientific Reports, 2018, 8, 14346.	3.3	7
57	Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 64-73.	0.9	6
58	Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer. Journal of Racial and Ethnic Health Disparities, 2019, 6, 133-142.	3.2	6
59	Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma. Annals of Hematology, 2018, 97, 851-863.	1.8	5
60	Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 294.e17-294.e25.	1.6	5
61	Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013: Findings from Texas and national SEER areas. Cancer Epidemiology, 2019, 58, 89-97.	1.9	5
62	Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients. Laryngoscope, 2020, 130, 1186-1194.	2.0	5
63	Estimating development cost of an interactive website based cancer screening promotion program. Evaluation and Program Planning, 2015, 50, 56-62.	1.6	4
64	Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients. Pharmacoeconomics, 2018, 36, 1355-1365.	3.3	4
65	Spatio-Temporal Variation of Gender-Specific Hypertension Risk: Evidence from China. International Journal of Environmental Research and Public Health, 2019, 16, 4545.	2.6	4
66	Economic Evaluation of Tailored Web versus Tailored Telephone-Based Interventions to Increase Colorectal Cancer Screening among Women. Cancer Prevention Research, 2020, 13, 309-316.	1.5	4
67	Estimating the cost of education and counseling programs. Patient Education and Counseling, 1991, 18, 179-188.	2.2	3
68	Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas. Oral Oncology, 2019, 96, 21-26.	1.5	3
69	Economic Methods in the Century Trial—a Comprehensive Lifestyle Modification Study for Managing Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2012, 5, 333-336.	2.4	2
70	Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer. Women's Health Issues, 2016, 26, 574-583.	2.0	2
71	Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. Journal of Lower Genital Tract Disease, 2019, 23, 102-109.	1.9	2
72	Palliative medicine integration in the USA: cancer centre executives' attitudes. BMJ Supportive and Palliative Care, 2023, 13, 199-208.	1.6	2

#	Article	IF	Citations
73	A stepped randomized trial to promote colorectal cancer screening in a nationwide sample of U.S. Veterans. Contemporary Clinical Trials, 2021, 105, 106392.	1.8	2
74	Prescribed Medicines. Journal of Pharmaceutical Marketing and Management, 1988, 3, 19-36.	0.1	1
75	Cost-effectiveness of alternate contact protocols and costs of mammography promotion interventions for women veterans. Evaluation and Program Planning, 2006, 29, 120-129.	1.6	1
76	Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e616-e623.	0.4	1
77	Economic Evaluation of Web- versus Telephone-based Interventions to Simultaneously Increase Colorectal and Breast Cancer Screening Among Women. Cancer Prevention Research, 2021, 14, 905-916.	1.5	1
78	Reply to "Letter to the Editor in response to the article, †The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis'― Oral Oncology, 2018, 86, 307.	1.5	0
79	Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States. Head and Neck, 2020, 42, 2321-2329.	2.0	0
80	An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas. Scientific Reports, 2021, 11, 1802.	3.3	0
81	Implementation costs of a multi-component program to increase human papillomavirus (HPV) vaccination in a network of pediatric clinics. Journal of Applied Research on Children, 2019, 10, .	0.2	O